Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 24, 2020 | Post-IPO Debt | $850M | — | — | — | Detail |
Jul 24, 2015 | Post-IPO Equity | $174M | — | — | — | Detail |
Jun 15, 2009 | Post-IPO Equity | $8.20M | 1 | — | — | Detail |
Jan 31, 2001 | IPO | $56M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jul 29, 2020
Thrive Earlier Detection
|
Series B | $257M | Biotechnology | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Excel Venture Management | — | Post-IPO Equity |
Exact Sciences has had 1 exits. Exact Sciences most notable exits include Thrive Earlier Detection
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Oct 27, 2020 | Thrive Earlier Detection | M&A | Biotechnology | Detail |
Exact Sciences has acquired 12 organizations. Their most recent acquisition was Sampleminded on Aug 1, 2017. They acquired Sampleminded for $3.20M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Aug 1, 2017
Sampleminded
|
Biotechnology | acquisition | $ 3.20M | Detail |
Feb 4, 2018
Armune BioScience
|
Biotechnology | acquisition | — | Detail |
Oct 18, 2018
Biomatrica
|
Biotechnology | acquisition | — | Detail |
Jul 29, 2019
Genomic Health
|
Biotechnology | acquisition | $ 2.80B | Detail |
Mar 3, 2020
Paradigm Diagnostics
|
Biotechnology | acquisition | — | Detail |